Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 8118 results found since Jan 2013.
Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development
Environ Res. 2023 Aug 31:117027. doi: 10.1016/j.envres.2023.117027. Online ahead of print.ABSTRACTThe latest advancements in oncology involves the creation of multifunctional nanostructures. The integration of nanoparticles into the realm of cancer therapy has brought about a transformative shift, revolutionizing the approach to addressing existing challenges and limitations in tumor elimination. This is particularly crucial in combating the emergence of resistance, which has significantly undermined the effectiveness of treatments like chemotherapy and radiotherapy. GO stands as a carbon-derived nanoparticle that is incre...
Source: Environmental Research - September 2, 2023 Category: Environmental Health Authors: Mohammad Saleh Sadeghi Faezeh Hosseini Sangrizeh Negar Jahani Mahdi Sadegh Abedin Soheila Chaleshgari Alireza Khodaei Ardakan Reza Baeelashaki Golnaz Ranjbarpazuki Parham Rahmanian Mohammad Arad Zandieh Noushin Nabavi Amir Reza Aref Shokooh Salimimoghadam Source Type: research
Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" Vaccine 40(41) (2022) 5971-5996
Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.06.084. Online ahead of print.NO ABSTRACTPMID:37659892 | DOI:10.1016/j.vaccine.2023.06.084
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Matthew Palmer Kota Katanoda Eiko Saito Cecilia Acuti Martellucci Shiori Tanaka Sayaka Ikeda Haruka Sakamoto Dorothy Machalek Julia M L Brotherton Jane S Hocking Source Type: research
Tumor vaccine based on extracellular vesicles derived from γδ-T cells exerts dual antitumor activities
This study provides a proof-of-concept for using the allogeneic γδ-T-EVs-based vaccine in cancer control.PMID:37654012 | DOI:10.1002/jev2.12360
Source: Cancer Control - September 1, 2023 Category: Cancer & Oncology Authors: Xiwei Wang Yanmei Zhang Yuet Chung Chloe Ran Tu Wenyue Zhang Xiaofeng Mu Manni Wang Godfrey Chi-Fung Chan Wing-Hang Leung Yu-Lung Lau Yinping Liu Wenwei Tu Source Type: research
N2 modified cap analogues as translation inhibitors and substrates for preparation of therapeutic mRNA
Eur Biophys J. 2023 Sep 1. doi: 10.1007/s00249-023-01676-7. Online ahead of print.ABSTRACTIn recent years many scientists have begun to focus on the mRNA molecule's emeregence as a new type of drug. Its fast-moving and successful career as a vaccine technology cannot be underestimated. mRNA provides new opportunities and allows for the rapid preparation of effective drugs at low cost. These extensive possibilities stem from a number of factors, but the small cap structure located at the 5' end of the mRNA is one contributing factor. Cap protects mRNA and ensures efficient recruitment to the biosynthesis machinery. Furtherm...
Source: European Biophysics Journal : EBJ - September 1, 2023 Category: Physics Authors: Karol Kurpiejewski Marzena Jankowska-Anyszka Renata Grzela Source Type: research
CAR T cells ignite antitumor immunity
Trends Immunol. 2023 Aug 29:S1471-4906(23)00156-4. doi: 10.1016/j.it.2023.08.002. Online ahead of print.ABSTRACTBroadening immune responses through antigen spreading remains the 'Holy Grail' of cancer immunotherapy. A study by Ma and colleagues reveals that vaccine boosting of chimeric antigen receptor (CAR)-T cells in mice promotes endogenous immunity and elicits antigen spread to eliminate antigenically heterogenous solid tumors through a mechanism crucially dependent on interferon (IFN)γ.PMID:37652814 | DOI:10.1016/j.it.2023.08.002
Source: Trends in Immunology - August 31, 2023 Category: Allergy & Immunology Authors: Darya Alizadeh Christine E Brown Source Type: research
Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT
Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.06.075. Online ahead of print.ABSTRACTMeasles outbreaks have raised concerns of fatal infections in immunocompromised patients. Canadian guidelines advise administration of live vaccines, such as measles, mumps, and rubella (MMR), two yearsafter hematopoietic stem cell transplant (HSCT) yet studies have not assessed eligibility based on medication contraindications. We retrospectively reviewed the charts of 72 autologous (auto-HSCT) and 68 allogeneic (allo-HSCT) recipients at the Windsor Regional Cancer Center to determine MMR reactivity and eligibilit...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Gopika Punchhi Rainbow Negus Hammad Saif Sharon Pritchard Olivia Owen Aman Sehmbi Caroline Hamm Source Type: research
CAR T cells ignite antitumor immunity
Trends Immunol. 2023 Aug 29:S1471-4906(23)00156-4. doi: 10.1016/j.it.2023.08.002. Online ahead of print.ABSTRACTBroadening immune responses through antigen spreading remains the 'Holy Grail' of cancer immunotherapy. A study by Ma and colleagues reveals that vaccine boosting of chimeric antigen receptor (CAR)-T cells in mice promotes endogenous immunity and elicits antigen spread to eliminate antigenically heterogenous solid tumors through a mechanism crucially dependent on interferon (IFN)γ.PMID:37652814 | DOI:10.1016/j.it.2023.08.002
Source: Trends in Immunology - August 31, 2023 Category: Allergy & Immunology Authors: Darya Alizadeh Christine E Brown Source Type: research
Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT
Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.06.075. Online ahead of print.ABSTRACTMeasles outbreaks have raised concerns of fatal infections in immunocompromised patients. Canadian guidelines advise administration of live vaccines, such as measles, mumps, and rubella (MMR), two yearsafter hematopoietic stem cell transplant (HSCT) yet studies have not assessed eligibility based on medication contraindications. We retrospectively reviewed the charts of 72 autologous (auto-HSCT) and 68 allogeneic (allo-HSCT) recipients at the Windsor Regional Cancer Center to determine MMR reactivity and eligibilit...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Gopika Punchhi Rainbow Negus Hammad Saif Sharon Pritchard Olivia Owen Aman Sehmbi Caroline Hamm Source Type: research
CAR T cells ignite antitumor immunity
Trends Immunol. 2023 Aug 29:S1471-4906(23)00156-4. doi: 10.1016/j.it.2023.08.002. Online ahead of print.ABSTRACTBroadening immune responses through antigen spreading remains the 'Holy Grail' of cancer immunotherapy. A study by Ma and colleagues reveals that vaccine boosting of chimeric antigen receptor (CAR)-T cells in mice promotes endogenous immunity and elicits antigen spread to eliminate antigenically heterogenous solid tumors through a mechanism crucially dependent on interferon (IFN)γ.PMID:37652814 | DOI:10.1016/j.it.2023.08.002
Source: Trends in Immunology - August 31, 2023 Category: Allergy & Immunology Authors: Darya Alizadeh Christine E Brown Source Type: research
